ABSTRACT
In this groundbreaking paper, Priestman and Baum introduced the use of the linear analogue selfassessment (LASA) tool to measure the subjective effects of treatment in women with advanced breast cancer. This paper introduced the concept that a simple technique could monitor the subjective benefit of treatment and compare in a readily comprehensible, convenient, and reliable way the subjective toxicities of different therapies. This paper was also one of the first to show that the subjective toxicity of cytotoxic chemotherapy (i) might not be related to patient age and (ii) actually diminished with successive courses of drugs.
